Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of Combined Anticoagulation and Antithrombotic Therapy in PAD
NCT04994223Phase 1Unknown
- Sponsor
- Armed Forces Post Graduate Medical Institute
- Start
- Jul 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Peripheral Arterial Disease (PAD) comparing Rivaroxaban + Aspirin with Placebo + Aspirin (2 arms). Primary endpoints: Acute Limb Ischemia at 1 year, Major Amputation for Vascular Reasons at 1 year and 3 more. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT04994223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994223.